Tezepelumab Injection bulk supplier for pharma manufacturers

Tezepelumab Injection 210 mg/1.91 mL Suppliers & Bulk Manufacturers

Available Forms: Pre-filled pen, pre-filled syringe (subcutaneous)

Available Strengths: 210 mg/1.91 mL

Pack Sizes: 1 pen or syringe

Reference Brands: Tezspire (Amgen / AstraZeneca)

Tezepelumab (Tezspire, Amgen and AstraZeneca) is a monthly injection for severe asthma that blocks TSLP, a signal at the top of the airway inflammation cascade. It is also approved for chronic rhinosinusitis with nasal polyps. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Tezepelumab Injection? List it or send an offer →

Product Description:

Tezepelumab is a monoclonal antibody against thymic stromal lymphopoietin (TSLP), a protein released by the airway lining when it meets allergens, viruses or pollution. TSLP sets off several inflammatory pathways at once. Because tezepelumab acts at this early point, it helps patients with both eosinophilic and non-eosinophilic (low-biomarker) severe asthma, unlike biologics that target a single pathway.

It is used as add-on maintenance treatment for severe asthma in adults and adolescents from 12 years, and approval for chronic rhinosinusitis with nasal polyps followed in 2025. The dose is 210 mg under the skin every four weeks, from a pre-filled pen or syringe. It reduces asthma attacks and hospital visits; it is not a rescue treatment for an acute attack.

Sourcing notes. Tezepelumab is patented and there is no biosimilar. It is a cold-chain product. Mepolizumab, benralizumab, dupilumab and omalizumab are also listed on PharmaTradz.

How Tezepelumab Injection is supplied today, and licensing ahead of patent expiry

Tezepelumab Injection is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Tezepelumab Injection, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Tezepelumab Injection supply →

Back to Listing